Clinical Trial: Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07679269) titled 'Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.' on June 25.

Brief Summary: The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination with other drugs. This study is intended for participants who are currently receiving alpelisib in a Novartis-sponsored clinical trial (parent study) and, in the Investigator's judgment, would benefit from continued treatment with alpelisib.

Study Start Date: Jan. 01, 2027

Study Type: INTERVENTIONAL

Condition: PIK3CA-Related Overgrowth Spectrum (PROS) Breast Neoplas...